# OnCo record emapalumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/emapalumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "emapalumab" ;
  schema:name "Emapalumab"@en ;
  schema:alternateName "Emapalumab-lzsg"@en, "NI-0501"@en, "Gamifant" ;
  schema:description "Emapalumab switches off interferon gamma, the signal behind the runaway immune activation of haemophagocytic lymphohistiocytosis (HLH), a condition that can also be triggered by lymphoma and by CAR-T therapy."@en ;
  schema:url <https://onco.cc/drugs/emapalumab/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Emapalumab> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=emapalumab>, <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761107> ;
  onco:status "established" ;
  onco:tag "gap-fill", "supportive-care" ;
  onco:modality "Anti-interferon-gamma monoclonal antibody" ;
  onco:approval "US 2018: Primary haemophagocytic lymphohistiocytosis, refractory, recurrent or progressive, or intolerant of conventional therapy" ;
  onco:cancers <https://onco.cc/cancers/histiocytoses/>, <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/technologies/car-t/> ;
  onco:companies <https://onco.cc/companies/sobi/> ;
  onco:terms <https://onco.cc/terms/crs/> ;
  onco:trials <https://onco.cc/trials/nct06550141/>, <https://onco.cc/trials/nct07567014/> .